株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

製薬・バイオテクノロジーにおける創薬段階での提携条件と契約動向

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2016

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 121841
出版日 ページ情報 英文 1,000+ pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。
Back to Top
製薬・バイオテクノロジーにおける創薬段階での提携条件と契約動向 Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2016
出版日: 2016年10月05日 ページ情報: 英文 1,000+ pages
概要

当レポートでは、世界の主要ヘルスケア企業による創薬段階での提携契約や合意内容について調査分析し、創薬段階で提携する理由、契約戦略と構造、支払戦略、契約活動、支払条件について提示するほか、主要契約、関係企業プロファイル、提携契約ディレクトリなどをまとめています。

エグゼクティブサマリー

第1章 イントロダクション

第2章 企業が創薬段階で提携する理由

  • イントロダクション
  • 創薬段階での提携の役割
  • 創薬・前臨床・臨床段階での契約の違い
  • 創薬段階での提携契約を締結する理由
  • 創薬段階での提携契約の見通し

第3章 創薬段階での契約戦略と構造

  • イントロダクション
  • どの段階で企業は提携するか
  • 初期・後期段階での提携 - リスク/コストの比較
  • 企業は創薬・前臨床・臨床段階での提携に何を費やすか
  • 単純 vs. 多要素の提携契約
  • 単純ライセンシング契約の構造
  • 多要素の前臨床段階での提携契約

第4章 創薬段階での提携の支払戦略

  • イントロダクション
  • 創薬段階での支払戦略
  • 支払オプション

第5章 創薬段階での契約形成の動向

  • イントロダクション
  • 長年にわたる創薬段階での提携
  • 大手製薬企業の創薬段階での契約活動
  • 大手バイオテクノロジー企業の創薬段階での契約活動
  • 創薬段階での提携:契約タイプ別
  • 創薬段階での提携:疾病タイプ別
  • 提携:創薬段階での技術タイプ別

第6章 創薬段階での提携の平均的な支払条件

  • イントロダクション
  • 創薬段階での支払条件のガイドライン
  • 創薬段階での支払 - 契約データ分析
  • 支払条件の分析

第7章 主な創薬段階での契約

  • イントロダクション
  • 主な創薬段階での契約:金額別

第8章 大手製薬企業/大手バイオテクノロジー企業の創薬段階での提携契約

  • イントロダクション
  • 大手製薬企業/大手バイオテクノロジー企業の創薬段階での提携契約を利用する方法
  • 大手製薬企業の創薬段階での提携企業プロファイル
  • 大手バイオテクノロジー企業の創薬段階での提携企業プロファイル

第9章 創薬段階での提携契約ディレクトリ

  • イントロダクション
  • 企業A〜Z
  • 契約タイプ別
  • 開発段階別
  • 治療領域別

第10章 創薬段階での契約形成ディレクトリ

  • イントロダクション
  • 契約:創薬段階別

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP2056

The ‘Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2016 ’ report.

The report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors product or technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest discovery agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all discovery stage partnering deals announced since 2010 including financial terms where available including over 3,000 links to online deal records of actual discovery partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of discovery stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner discovery stage compounds/products.

Chapter 3 provides an overview of discovery stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in discovery stage deals.

Chapter 5 provides a review of discovery stage deal making since 2010. Deals activity is reviewed by year, therapeutic area, technology type, as well as most active dealmakers.

Chapter 6 provides a detailed analysis of discovery stage payment terms including headline, upfront, milestone and royalty rates.

Chapter 7 provides a review of the leading discovery stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 8 provides a comprehensive listing of the top 50 most active discovery stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 9 provides a comprehensive and detailed review of discovery stage partnering deals signed and announced since 2010, where a contract document is available in the public domain.

Chapter 10 provides a comprehensive directory of discovery stage partnering deals since 2010.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous tables and figures that illustrate the trends and activities in discovery stage partnering and deal making since 2010.

In addition, a comprehensive appendix of all discovery deals since 2010 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of discovery stage products and compounds.

Key benefits

‘Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2016 ’ provide the reader with the following key benefits:

  • In-depth understanding of discovery stage deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of discovery stage agreements with numerous real life case studies
  • Insight into the terms included in a discovery stage agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

‘Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2016 ’ is intended to provide the reader with an in-depth understanding and access to discovery stage deal trends and structure of deals entered into by leading companies worldwide.

‘Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2016 ’ include:

  • Trends in discovery stage dealmaking in the biopharma industry since 2010
  • Analysis of discovery stage deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life discovery stage deals
  • Access to over 3,000 discovery stage deals
  • The leading discovery stage deals by value since 2010
  • Most active discovery stage dealmakers since 2010
  • The leading discovery stage partnering 2010

In ‘Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2016 ’, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal type
  • Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2016 ’ report provides comprehensive access to available deals and contract documents for over 3,000 discovery stage deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner at discovery stage?

  • 2.1. Introduction
  • 2.2. The role of discovery stage partnering
    • 2.2.1. In-licensing at discovery stage
    • 2.2.2. Out-licensing at discovery stage
  • 2.3. Difference between discovery, preclinical and clinical stage deals
  • 2.4. Reasons for entering into discovery stage partnering deals
    • 2.4.1. Licensors reasons for entering discovery stage deals
    • 2.4.2. Licensees reasons for entering discovery stage deals
  • 2.5. The future of discovery stage partnering deals

Chapter 3 - Discovery stage deal strategies and structure

  • 3.1. Introduction
  • 3.2. At what stage do companies partner?
    • 3.2.1. Partnering early in pharmaceutical/biotech
      • 3.2.1.1. Discovery and preclinical stage partnering case studies
        • 3.2.1.1.a. Case study: LEO Pharma - 4SC
        • 3.2.1.1.b. Case study: Heptares Therapeutics - Cubist
        • 3.2.1.1.c. Case study: Incyte - Agenus Bio
        • 3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec
      • 3.2.2. Partnering later in pharmaceutical/biotech
        • 3.2.2.1. Clinical stage partnering case studies
          • 3.2.2.1.a. Case study: Servier - GeNeuro
          • 3.2.2.1.b. Case study: Teva - Xenon Pharmaceuticals
          • 3.2.2.1.c. Case study: AstraZeneca - Ardelyx
          • 3.2.2.1.d. Case study: Baxter - Onconova Therapeutics
  • 3.3. Early and later stage partnering - a risk/cost comparison
  • 3.4. What do companies spend on discovery, preclinical and clinical stage partnering?
  • 3.5. Pure versus multi-component partnering deals
  • 3.6. Pure licensing agreement structure
    • 3.6.1. Example pure licensing agreements
      • 3.6.1.a. Case study : Pfizer - Spark Therapeutics
      • 3.6.1.b. Case study : Contrafect - Trellis Bioscience
  • 3.7. Multicomponent discovery stage partnering agreements
    • 3.7.1.a. Example multicomponent early stage clauses
    • 3.7.1.a. Case study: Tracon - Boehringer Ingelheim - Macrogenics
    • 3.7.1.b. Case study: Fibrocell Science - Intrexon

Chapter 4 - Discovery stage partnering payment strategies

  • 4.1. Introduction
  • 4.2. Discovery stage payment strategies
  • 4.3. Payment options
    • 4.3.1. Headline values
    • 4.3.2. Upfront payments
      • 4.3.2.1. Conditionality of upfront payments
    • 4.3.3. Loans
    • 4.3.4. Convertible loans
    • 4.3.5. Equity
    • 4.3.6. R&D funding
    • 4.3.7. Licensing fees
    • 4.3.8. Milestone payments
    • 4.3.9. Royalty payments
      • 4.3.9.1. Issues affecting royalty rates
      • 4.3.9.2. Royalties on combination products
        • 4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech
      • 4.3.9.3. Guaranteed minimum/maximum annual payments
      • 4.3.9.4. Royalty stacking
      • 4.3.9.5. Royalties and supply/purchase contracts
    • 4.3.10. Quids
    • 4.3.11. Option payments

Chapter 5 - Trends in discovery stage deal making

  • 5.1. Introduction
  • 5.2. Discovery stage partnering over the years
    • 5.2.1. Attributes of discovery deals
  • 5.3. Discovery stage partnering by deal type
  • 5.4. Discovery stage partnering by disease type
  • 5.5. Partnering by discovery stage technology type
  • 5.6. Discovery stage partnering by most active company, 2010 to 2016

Chapter 6 - Payment terms for discovery stage partnering

  • 6.1. Introduction
  • 6.2. Guidelines for discovery stage payment terms
    • 6.2.1. Upfront payments
    • 6.2.2. Milestone payments
    • 6.2.3. Royalty payments
  • 6.3. Discovery stage payment terms - deal data analysis
    • 6.3.1. Public data
    • 6.3.2. Survey data
  • 6.4. Payment terms analysis
    • 6.4.1. Discovery stage headline values
    • 6.4.2. Discovery stage deal upfront payments
    • 6.4.3. Discovery stage deal milestone payments
    • 6.4.4. Discovery stage royalty rates

Chapter 7 - Leading discovery stage deals

  • 7.1. Introduction
  • 7.2. Top discovery stage deals by value

Chapter 8 - Top 50 most active discovery stage dealmakers

  • 8.1. Introduction
  • 8.2. Top 50 most active discovery stage dealmakers

Chapter 9 - Discovery stage partnering contracts directory

  • 9.1. Introduction
  • 9.2. Discovery stage deals with contracts 2010 to 2016

Chapter 10 - Discovery stage deal making by development stage

  • 10.1. Introduction
  • 10.2. Deals by discovery stage

Appendices

Appendix 1 - Discovery stage dealmaking by companies A-Z

Appendix 2 - Discovery stage dealmaking by industry sector

Appendix 3 - Discovery stage dealmaking by stage of development

Appendix 4 - Discovery stage dealmaking by therapy area

Appendix 5 - Discovery stage dealmaking by technology type

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
  • Figure 2: Agreements signed by phase of development (2010-2015), % of all deals where stage disclosed
  • Figure 3: Components of the pure licensing deal structure
  • Figure 4: Payment options for discovery stage partnering deals
  • Figure 5: Issues affecting royalty rates
  • Figure 6: Discovery stage partnering frequency 2010- 2016
  • Figure 7: Discovery stage partnering by deal type since 2010
  • Figure 8: Discovery stage partnering by disease type since 2010
  • Figure 9: Discovery stage partnering by technology type since 2010
  • Figure 10: Top 50 most active discovery stage dealmakers, 2010 to 2016
  • Figure 11: Review of median upfront payments for discovery stage deals
  • Figure 12: Review of median milestone payments for discovery stage deals
  • Figure 13: Review of median royalty payments for discovery stage deals
  • Figure 14: Discovery stage deals with a headline value
  • Figure 15: Discovery stage deals with an upfront value
  • Figure 16: Discovery stage deals with a milestone value
  • Figure 17: Discovery stage deals with a royalty rate value
  • Figure 18: Top discovery stage deals that exceeds $1 billion in deal value since 2010
  • Figure 19: Most active discovery stage dealmakers 2010 to 2016
Back to Top